DOCSLIB.ORG

Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience Published OnlineFirst April 30, 2012; DOI: 10.1158/1078-0432.CCR-11-1275 Clinical Cancer Review Research Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye Abstract Antiangiogenic therapies are now well established in oncology clinical practice; however, despite initial optimism, the results of late-phase trials, especially in the adjuvant setting, have largely proved disap- pointing. In the context of metastatic disease, resistance to antiangiogenic agents arises through a range of mechanisms, including the development of alternative angiogenic pathways. One of the proposed strategies to overcome this resistance is to combine antiangiogenic agents with different mechanisms of action. Early- phase clinical trials assessing the tolerability and efficacy of different combinations of antiangiogenic drugs, including those that target the VEGF pathway or the angiopoietins, as well as vascular disrupting agents, are increasing in number. An example of this strategy is the combination of sorafenib and bevacizumab, which has elicited major responses in different tumor types, including ovarian carcinoma and glioblastoma. However, overlapping and cumulative toxicities pose a real challenge. This review summarizes the preclinical rationale for this approach and current clinical experience in combining antiangiogenic therapies. Clin Cancer Res; 18(14); 3750–61. Ó2012 AACR. Introduction mab was also shown to prolong the time to progression as The importance of tumor angiogenesis has been recog- monotherapy (10) and in combination with interferon (13). nized for almost 80 years (1), and 4 decades ago, Folkman Tyrosine kinase inhibitors (TKI) targeting VEGFR, such as (2) proposed it as a therapeutic target, recognizing its critical sunitinib (8) and sorafenib (5), as monotherapies have also role in the growth and survival of tumors larger than 1 mm3. produced an OS benefit for patients with mRCC. Similarly, However, it is only in the last 10 years that this knowledge has sorafenib has now become the standard of care for advanced successfully translated to inhibitory strategies in clinical hepatocellular carcinoma because it was shown to increase practice. Endothelial cells (EC) have been assumed to show OS compared with placebo (14). However, in other tumors, genomic stability in comparison with the multiple somatic despite the initial benefit seen in some patients treated with mutations acquired within tumors during their growth, VEGF pathway inhibitors, complete responses have not leading to the belief that ECs would avoid resistance to generally been documented, and most patients will experi- therapy (3, 4). Targeting of angiogenesis has been validated ence tumor progression and succumb to their disease. More- by evidence of efficacy from several agents directed against over, attempts to use these drugs in the adjuvant setting (e.g., components of the main proangiogenic VEGF signaling in colorectal cancer) have thus far been disappointing, pathway at the level of the ligand (VEGF) and its receptors yielding the same results as chemotherapy alone (15). [VEGFR (5–10)]. Bevacizumab, a monoclonal antibody Lessons could be learned from the paradigm of mRCC (mAb) targeting VEGF, was shown to result in improved management, in which antiangiogenic strategies have been overall survival (OS) in metastatic colorectal and lung cancer most successfully adopted in routine clinical practice. when combined with chemotherapy (6, 9), and progression- Acquired resistance to anti-VEGF therapy may mean that free survival (PFS) in metastatic breast and ovarian cancer the order in which targeted agents are introduced to patients (11, 12). In metastatic renal cell cancer (mRCC), bevacizu- is important, such that a survival benefit may be derived from sequential monotherapy with multitargeted TKIs (16). An analysis of a prospective trial (17), numerous retrospec- Authors' Affiliation: Division of Clinical Sciences, Institute of Cancer tive studies, and a subgroup analysis of expanded-access Research and Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom programs for sorafenib suggested that there is an increase in Note: Victor Moreno Garcia and Bristi Basu contributed equally to this PFS for a TKI switch in mRCC (18). These data support a lack article. of cross-resistance between multitargeted TKIs; however, Corresponding Author: Victor Moreno, Drug Development Unit, Division ongoing sorafenib/sunitinib crossover trials, such as of Clinical Sciences, Institute of Cancer Research/The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom. Phone: SWITCH (www.ClinicalTrials.gov; NCT00732914), may 44-020-8642-3539; Fax: 44-020-8642-6011; E-mail: address these issues more definitively. [email protected] An alternative to using VEGF-targeting agents sequent- doi: 10.1158/1078-0432.CCR-11-1275 ially is to focus on combining agents that affect different Ó2012 American Association for Cancer Research. aspects of angiogenesis. Our knowledge about the 3750 Clin Cancer Res; 18(14) July 15, 2012 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2012 American Association for Cancer Research. Published OnlineFirst April 30, 2012; DOI: 10.1158/1078-0432.CCR-11-1275 Combining Antiangiogenic Therapies complexity of angiogenesis is growing rapidly, and it is Translational Relevance recognized that VEGF-independent drivers include multiple Targeting angiogenesis in cancer has been shown to interactions among diverse growth factors and receptors increase overall and/or progression-free survival for sev- involving ECs, NOTCH/d-like ligand 4 (DLL4), angiopoie- eral tumor types, including renal, ovarian, colon, lung, tin (Ang)-Tie, placental growth factor (PlGF), tumoral cells and breast cancers. However, many tumors are intrinsi- (SDF1/CXCR4), pericytes [platelet-derived growth factor cally resistant to antiangiogenic therapies. Other tumors, (PDGF) and transforming growth factor (TGF-b)], extracel- after an initial response, acquire secondary resistance lular matrix (ECM) components (integrins and cadherins), leading to further tumor growth. There is an urgent need inflammatory cells (tumor-associated macrophages and to identify mechanisms to overcome this resistance, and Tie-2–expressing monocytes), and bone-marrow–derived preclinical studies suggest that combining different anti- cells (Fig. 1; reviewed in refs. 19 and 20). A new paradigm angiogenics could be a suitable strategy. However, over- for the development of malignant angiogenesis was recently lapping toxicities are an issue of major concern. Early proposed based on the finding in glioblastoma multiforme clinical experience shows that trials combining different (GBM) that tumor ECs can arise directly through differen- þ þ antiangiogenics are complex, and schedules cannot be tiation of CD133 /CD144 tumor cells (21). In addition, easily extrapolated from single-agent studies. Careful preclinical work is providing insights into mechanisms clinical development of these combinations will be of resistance to antiangiogenic therapy. These mechanisms crucial to assess the relevance of positive data coming are described as being intrinsic (preexisting) or adaptive from preclinical models. (acquired), and they may explain why some tumors do not respond from the outset and why others progress after initial Indirect inhibition Vertical Horizontal VEGF VEGF ANG VEGFR NRP TIE2 Proliferation NOTCH Survival DLL4 Endothelial cell PDGFR Integrin ECM MMP Invasion Direct inhibition VDA © 2012 American Association for Cancer Research Figure 1. Schematic diagram showing theoretical combinations targeting angiogenesis. MMP, matrix metalloproteinase; NRP, neuropilin. www.aacrjournals.org Clin Cancer Res; 18(14) July 15, 2012 3751 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2012 American Association for Cancer Research. Published OnlineFirst April 30, 2012; DOI: 10.1158/1078-0432.CCR-11-1275 Moreno Garcia et al. Table 1. Angiogenesis inhibitors Group Name Action MTD/phase II dose as single agent VEGFR and PDGFR AEE788 VEGFR-2, EGFR 550 mg qd TKIs Axitinib (AG-013736) VEGFR-1,2,3; PDGFR-b; c-KIT 5 mg b.i.d. Intedanib (BIBF 1120) VEGFR-1,2,3; PDGFR-a,b 250 mg b.i.d. Brivanib (BMS-540215) VEGFR-2,3; FGFR1,2 800 mg qd Cediranib (AZD2171) VEGFR-1,2,3 45 mg qd CP 547,632 VEGFR-2 200 mg qd Dovitinib (TKI258) VEGFR-1,2,3; PDGFR-b; c-KIT; 125 mg qd FLT3; FGFR1,2,3 Motesanib (AMG706) VEGFR-1,2,3; PDGFR-b; c-KIT 125 mg qd OSI 930 VEGFR-2; c-KIT 500 mg b.i.d. Pazopanib (GW786034) VEGFR-1,2,3; PDGFR; c-KIT 800 mg qd Semaxinib (SU5416) VEGFR-2, RET 145 mg/m2 q1w Sorafenib (BAY 43-9006) VEGFR-2,3; PDGFR-b, RET, c-KIT, 400 mg b.i.d. RAF SU6668 VEGFR-2; FGFR1, c-KIT, PDGFR-b 100 mg/m2 Sunitinib (SU11248) VEGFR-1,2; PDGFR-b; c-KIT; FLT3; 50 mg qd 4w/6w PDGFR-a,b Telatinib (BAY 57-9352) VEGFR-2,3; PDGFR-b 900 mg b.i.d. Vandetanib (AZD6474) VEGFR-2, EGFR 300 mg qd Vatalanib (PTK/ZK) VEGFR-1,2,3; PDGFR; c-KIT 1200 mg qd Anti-VEGFR Ramucirumab (IMC-1121B) mAb against VEGFR-2 13 mg/kg q1w Anti-VEGF Aflibercept (VEGF-trap) Soluble VEGFR-1,2 4 mg/kg q2w i.v. 1600 mg/kg q1w s.c. Bevacizumab mAb against VEGF-A 5–15 mg/kg q2w VEGF-AS (Veglin) VEGF antisense oligonucleotide 85 mg/m2 days 1–5 q2w VDA ABT-751 Tubulin binding 250 mg qd; 150 mg b.i.d. ASA404 (DMXAA) Flavonoid 1000–2000 mg/m2 q1w CYT 997 Tubulin binding 202 mg/m2 q3w EPC2407 Tubulin binding 13 mg/m2 days 1–3 q3w Fosbretabulin (CA4P) Tubulin binding 52 mg/m2 days q3w MN-029 Tubulin binding 180 mg/m2 q1w (3w/4w) MPC-6827 Tubulin binding 3.3 mg/m2 q1w NPI-2358 Tubulin binding 30 mg/m2 q1w (3w/4w) Ombrabulin (AVE8062) Tubulin binding 22 mg/m2 q3w OXi4503 (CA1P) Tubulin binding ND TZT 1027 Tubulin binding 2.7 mg/m2 q3w ZD 6126 Tubulin binding 80 mg/m2 q2w Integrin inhibitors ATN-161 Anti-a5b1 16 mg/kg 3x/q1w Cilengitide Anti-avb3 and anti-avb5 600 mg/m2 2x/q1w (EMD 121974) CNTO95 Anti-av 10 mg/kg days 0, 28, 35, and 42, and q3w thereafter Etaracizumab Anti-avb3 6 mg/kg 2x/q1w Volociximab Anti-a5b1 15 mg/kg q1w MMP inhibitors BMS-275291 MMP-1, -2, -7, -9, -14 1200 mg qd Marimastat (BB-2516) Pan-MMP inhibitor 50 mg b.i.d.
Load more

Recommended publications
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • WO 2015/123595 Al 20 August 2015 (20.08.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/123595 Al 20 August 2015 (20.08.2015) P O P C T (51) International Patent Classification: nut Creek, California 94597 (US). SPANGLER, Ben¬ A61K 31/4025 (2006.01) A61P 33/06 (2006.01) jamin B.; 525 Nelson Rising Lane, Apt. 509, San Fran C07D 407/12 (2006.01) cisco, California 94158 (US). WELLS, James A.; 1341, Columbus Ave., Burlingame, California 94010 (US). (21) International Application Number: PCT/US2015/015948 (74) Agents: NOMURA, Anson M. et al; Mintz Levin Cohn Ferris Glovsky and Popeo PC, 3580 Carmel Mountain (22) International Filing Date: Road, Suite 300, San Diego, CA 92130 (US). 13 February 2015 (13.02.2015) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 61/940,295 14 February 2014 (14.02.2014) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (71) Applicant: THE REGENTS OF THE UNIVERSITY KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, OF CALIFORNIA [US/US]; 1111 Franklin Street, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, Twelfth Floor, Oakland, California 94607-5200 (US).
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • W W W .Bio Visio N .Co M
    Biosimilar Monoclonal Antibodies Human IgG based monoclonal antibodies (mAbs) are the fastest-growing category of therapeutics for cancer therapy. Several mechanisms of tumor cell killing by antibodies (mAbs) can be summarized as: direct action through receptor blockade or induction of apoptosis; immune-mediated cell killing by complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) or regulation of T cell function. Several monoclonal antibodies have received FDA approval for the treatment of a variety of solid tumors and hematological malignancies. BioVision is pleased to offer research grade biosimilars in human IgG format for your research needs. Our monoclonal antibodies are manufactured using recombinant technology with variable regions from the therapeutic antibody to achieve similar safety and efficacy. These antibodies can be used as controls for preclinical lead identification and potency assays for the development of novel therapeutics. Antibody Name Cat. No. Trade Name Isotype Size Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Ab A1092 - IgG4 200 µg Anti-Beta-galactosidase, Human IgG1 Ab A1104 - IgG1 200 µg Anti-C5 (Eculizumab), Humanized Ab A2138 - IgG2/4 100 μg Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Ab A1096 - IgG1 200 µg Anti-CCR4 (Mogamulizumab), Human IgG1, kappa Ab A2005 - IgG1 200 μg Anti-CD11a (Efalizumab), Human IgG1 Ab A1089 Raptiva IgG1 200 µg Anti-CD20 (Rituximab), Chimeric Ab A1049 Mabthera IgG1 100 µg Anti-CD22 (Epratuzumab), Human IgG1 Ab A1445 LymphoCide IgG1 200 µg Anti-CD3 epsilon (Muromonab), Mouse IgG2a, kappa Ab A2008 - IgG2a 200 μg Anti-CD33 (Gemtuzumab), Human IgG4 Ab A1443 Mylotarg IgG4 200 µg Anti-CD38 (Daratumumab), Human IgG1 Ab A2151 Darzalex IgG1 100 μg www.biovision.com 155 S.
    [Show full text]
  • The Constituents and Potential Targets Of
    genesi ino s & rc a M C u t f a o g Weber, J Carcinogene Mutagene 2013, S13 l Journal of Carcinogenesis & e a n n e DOI: 4172/2157-2518.S13-006 r s u i s o J Mutagenesis ISSN: 2157-2518 ReviewResearch Article Article OpenOpen Access Access The Constituents and Potential Targets of the Extracellular Matrix: Implications for Carcinogenesis and Cancer Treatment Weber CE, Driver J, Franzen CA, Mascarenhas JB, Mi Z, Gupta GN, Wai PY and Kuo PC* Department of Surgery, Loyola University, Maywood, Ireland Abstract The dense extracellular matrix consists of a multitude of proteins with important implications in tumorogenesis that extend beyond the maintenance of tissue integrity. Several of the main macromolecular constituents- proteoglycans, collagens, integrins, and syndecans will be discussed in this review, with particular attention to their roles in tumor initiation, invasion, angiogenesis, and metastasis. In addition, a brief synopsis of the role of enzymes that remodel the extracellular matrix will be provided. Finally, specific examples of targeted molecular therapies: anti-integrin agents, MMP inhibitors, and hyaluronidase will be discussed. Keywords: Extracellular matrix; Proteoglycans; Integrins; Syndecans; and mechanical signaling in the Tumor Microenvironment (TME). Matrix metalloproteinases; Hyaluronidase These cues modulate many aspects of carcinogenesis, from tumor formation to tumor migration and invasion to distant metastasis [1,2]. Abbreviations: ECM- Extracellular Matrix; BM- Basement Communication between the ECM and cancer cells occurs directly Membrane; PG- Proteoglycan; HSPG- Heparan Sulfate Proteoglycan; through cell-ECM adhesion molecules such as integrins and syndecans GAG- Glycosaminoglycan; MMP- Matrix Metalloproteinase; ADAM- and also indirectly through ECM bound growth factors and transmitted A Disintegrin And Metalloproteinase; TIMP- Tissue Inhibitor of mechanical forces.
    [Show full text]
  • Integrins As Therapeutic Targets: Successes and Cancers
    cancers Review Integrins as Therapeutic Targets: Successes and Cancers Sabine Raab-Westphal 1, John F. Marshall 2 and Simon L. Goodman 3,* 1 Translational In Vivo Pharmacology, Translational Innovation Platform Oncology, Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany; [email protected] 2 Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; [email protected] 3 Translational and Biomarkers Research, Translational Innovation Platform Oncology, Merck KGaA, 64293 Darmstadt, Germany * Correspondence: [email protected]; Tel.: +49-6155-831931 Academic Editor: Helen M. Sheldrake Received: 22 July 2017; Accepted: 14 August 2017; Published: 23 August 2017 Abstract: Integrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGFβ, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological intervention, as proven by the clinical success of seven drugs targeting them. The six drugs on the market in 2016 generated revenues of some US$3.5 billion, mainly from inhibitors of α4-series integrins. In this review we examine the current developments in integrin therapeutics, especially in cancer, and comment on the health economic implications of these developments. Keywords: integrin; therapy; clinical trial; efficacy; health care economics 1. Introduction Integrins are heterodimeric cell-surface adhesion molecules found on all nucleated cells. They integrate processes in the intracellular compartment with the extracellular environment. The 18 α- and 8 β-subunits form 24 different heterodimers each having functional and tissue specificity (reviewed in [1,2]).
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]
  • Integrin Alpha5 in Human Breast Cancer Is a Mediator of Bone Metastasis and a Therapeutic Target for the Treatment of Osteolytic Lesions
    Oncogene (2021) 40:1284–1299 https://doi.org/10.1038/s41388-020-01603-6 ARTICLE Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions 1,2,3 1,2 4 5,6 3 Francesco Pantano ● Martine Croset ● Keltouma Driouch ● Natalia Bednarz-Knoll ● Michele Iuliani ● 3 1,2 5 1,2 4 3 Giulia Ribelli ● Edith Bonnelye ● Harriet Wikman ● Sandra Geraci ● Florian Bonin ● Sonia Simonetti ● 3 2,7 1,2 5 3 3 Bruno Vincenzi ● Saw See Hong ● Sofia Sousa ● Klaus Pantel ● Giuseppe Tonini ● Daniele Santini ● Philippe Clézardin 1,2,8 Received: 10 May 2020 / Revised: 26 November 2020 / Accepted: 3 December 2020 / Published online: 8 January 2021 © The Author(s) 2021. This article is published with open access Abstract Bone metastasis remains a major cause of mortality and morbidity in breast cancer. Therefore, there is an urgent need to better select high-risk patients in order to adapt patient’s treatment and prevent bone recurrence. Here, we found that integrin alpha5 (ITGA5) was highly expressed in bone metastases, compared to lung, liver, or brain metastases. High ITGA5 1234567890();,: 1234567890();,: expression in primary tumors correlated with the presence of disseminated tumor cells in bone marrow aspirates from early stage breast cancer patients (n = 268; p = 0.039). ITGA5 was also predictive of poor bone metastasis-free survival in two separate clinical data sets (n = 855, HR = 1.36, p = 0.018 and n = 427, HR = 1.62, p = 0.024). This prognostic value remained significant in multivariate analysis (p = 0.028).
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0258889 A1 Douglas Et Al
    US 20070258889A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0258889 A1 Douglas et al. (43) Pub. Date: Nov. 8, 2007 (54) NOVEL NANOPARTICLES AND USE Related U.S. Application Data THEREOF (60) Provisional application No. 60/736,041, filed on Nov. 9, 2005. Provisional application No. 60/831,109, filed (75) Inventors: Trevor Douglas, Bozeman, MT (US); on Jul. 14, 2006. Peter Suci, Bozeman, MT (US); Mark J. Young, Bozeman, MT (US) Publication Classification (51) Int. Cl. A6IR 9/14 (2006.01) Correspondence Address: A61R 49/14 (2006.01) DORSEY & WHITNEY LLP A6II 5L/08 (2006.01) 555 CALIFORNIA STREET, SUITE 1000 (52) U.S. Cl. ....................... 424/1.37: 424/499: 424/9.34; SUTE 1 OOO 977/773 SAN FRANCISCO, CA 94104 (US) (57) ABSTRACT Assignee: Montana State University, Bozman, MT The present invention is directed to novel compositions and (73) methods utilizing delivery agents or nanoparticles that include protein cages with modified and/or unmodified (21) Appl. No.: 11/558,393 Subunits and various agents, such as therapeutic and/or imaging agents located on the interior and/or exterior Sur (22) Filed: Nov. 9, 2006 face of the protein cages. sHsp Loop Insert N-TerminuS > s C-Terminus CCMV C-Terminus--> * Patent Application Publication Nov. 8, 2007 Sheet 1 of 29 US 2007/0258889 A1 sHsp Loop Insert N-Terminus > * D & C-Terminus CCMV C-Terminus--> y Loop Insert.) N-Terminus os FIG. 1 on 3... O O OH O O DMF. disopropyleyamine --O Horsa X = M OMO 1 M. HO s o O NH, N/Yssn1 HN-Jo.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Biosimilar Antibodies & ELISA Kits
    Biosimilar Antibodies & ELISA Kits Tech Help: Email: [email protected] | Toll Free: 800.891.9699 (US Only) | Human IgG based monoclonal antibodies (mAbs) are the fastest-growing category of therapeutics for cancer therapy. With various degree of humanization of the antibody developed from murine, large foreign biologic antibodies are able to detect and kill tumor cells. Several mechanisms of tumor cell killing by antibodies (mAbs) can be sumarized as: direct action through receptor blockade or induction of apoptosis; immune-mediated cell killing by complement-dependent cytotoxicty (CDC), antibody-dependent cellular cytotoxicity (ADCC) or regulation of T cell function. Several monoclonal antibodies have received FDA approval for the treatment of a variety of solid tumors and hematological malignancies. BioVision is pleased to offer research-grade biosimilar antibodies and ELISA kits for your research needs. These antibodies can be used as controls for preclinical lead identification and potency assays for the development of novel therapeutics; ELISA kits can be used to identify biomarkers for (non-)response and risk factors for adverse drug reactions. Granulocyte Monocyte Complement Tumor antigen Tumor cell MAC ITAM NK Cell Figure A: Immune-mediated effects of tumour-specific IgG Figure B: Direct effects of tumour-specific IgG 2 Biosimilar Antibodies Research grade biosimilars-monoclonal antibodies are manufactured using recombinant technology. These antibodies are ideal research tools for preclinical lead identification and potency assays for the development of novel therapeutics. Key Features: • No additives: Supplied in PBS buffer with preservative (0.02% Proclin™ 300) • High purity: >98% purity as determined by SDS-PAGE • Low endotoxin: <1 EU/µg as determined by the LAL-method • Versatile: Can be used for various applications; ELISA, Neutralization, Flow Cytometry, IHC, IF A B C D Figure: Immunofluorescent and Immunohistochemical staining using Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody (Cat.
    [Show full text]